You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

34 search results for: COPD

GOLD 2024 Diagnosis and Assessment of <b>COPD</b>
videoanimation

GOLD 2024 Diagnosis and Assessment of COPD

Pulmonology
This short video presentation outlines the diagnosis and assessment of COPD according to the 2024 GOLD report, focusing on clinical features and assessment goals.
View more
Worsening Disease Results in a Vicious Cycle of <b>COPD</b>
interactivity

Worsening Disease Results in a Vicious Cycle of COPD

Pulmonology
Learn about the disease burden and heterogeneity of COPD
View more
Pathways to Disease: Inflammation in <b>COPD</b>
interactivity

Pathways to Disease: Inflammation in COPD

Pulmonology
Learn about the pathophysiology of COPD and the involvement of chronic inflammation on the airways
View more
The Heterogeneity of Underlying Inflammation in Patients With <b>COPD</b>
expert video

The Heterogeneity of Underlying Inflammation in Patients With COPD

Pulmonology
Join global expert Professor Ian Pavord as he discusses the heterogeneity of underlying inflammation in patients with COPD.
View more
What Differentiates <b>COPD</b> Exacerbations From Asthma Exacerbations?
expert video

What Differentiates COPD Exacerbations From Asthma Exacerbations?

Pulmonology
Join global expert Dr. Eric Bateman as he discusses how exacerbations in patients with COPD are different than exacerbations in patients with asthma.
View more
Impact of Exacerbations in <b>COPD</b>
expert video

Impact of Exacerbations in COPD

Type 2 Inflammation
Dr. Stephanie Christenson discusses the association between COPD exacerbations and the increased risks of morbidity and mortality
View more
ERS 2024 | Targeting IL-33 in <b>COPD</b>: Exploring New Frontiers for <b>COPD</b> Management
expert video

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

Pulmonology
Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, discuss preclinical findings, and review ongoing clinical research targeting IL-33 in COPD.
View more
ERS 2024 | Living With <b>COPD</b>: Linking Inflammation with Patient Burden
expert video

ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

Pulmonology
Professor Henrik Watz explores the complex relationship between inflammation and COPD, highlighting its impact on patients' health and overall quality of life.
View more
What Is The <b>COPD</b> Vicious Cycle?
expert video

What Is The COPD Vicious Cycle?

Pulmonology
Dr. Nicola Hanania explains the vicious cycle of exacerbations and lung function decline observed in COPD.
View more
ERS 2023 | Heterogeneity of Inflammatory Pathways in <b>COPD</b>
expert video

ERS 2023 | Heterogeneity of Inflammatory Pathways in COPD

Pulmonology
Dr. Stephanie Christenson shares an overview of inflammatory pathways underlying COPD, including type 2 inflammation.
View more
ERS 2024 | Understanding the Complex Pathophysiology of <b>COPD</b>
expert video

ERS 2024 | Understanding the Complex Pathophysiology of COPD

Pulmonology
Professor Klaus Rabe delves into the intricate inflammatory pathways and cellular mechanisms that drive the development and progression of COPD.
View more
ERS 2024 | Unraveling the Role of Type 2 Inflammation in <b>COPD</b>
expert video

ERS 2024 | Unraveling the Role of Type 2 Inflammation in COPD

Pulmonology
Professor Mona Bafadhel presents a comprehensive overview of type 2 inflammation in COPD, exploring its underlying mechanisms, clinical manifestations, and implications for patient outcomes.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BelgiumChange country/region